- Accesswire•5 days agoResearch Reports Initiated on Healthcare Stocks Immunovaccine, IntelliPharmaCeutics International, Cardiome Pharma, and Aeterna Zentaris
LONDON, UK / ACCESSWIRE / January 12, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...
- CNW Group•28 days ago
Cardiome Announces Commercial Launch of XYDALBA™ (dalbavancin) in Germany
- PR Newswire•28 days ago
VANCOUVER, Dec. 20, 2016 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced that it has initiated the commercial launch of XYDALBA™ (dalbavancin hydrochloride) in Germany ahead of the expected 2017 launch, and that it has made its first sales of the drug to German hospitals. XYDALBA is approved by the European Medicines Agency for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. "We are pleased to continue the roll-out, especially in the German market, of XYDALBA beyond the previously announced launch in the UK," said Hugues Sachot, Cardiome's Senior VP Commercial commenting on the XYDALBA launch in Germany.
COM.TO : Summary for CARDIOME PHARMA CORP - Yahoo Finance
Cardiome Pharma Corp. (COM.TO)
Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||3.75 - 3.99|
|52 Week Range||3.25 - 9.31|
|PE Ratio (TTM)||-3.83|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|